相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study
Sara Blanco-Dorado et al.
PHARMACOTHERAPY (2020)
Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms
Guangting Zeng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia
Peijun Yvonne Zhou et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Protective effects of glucocorticoid on liver injury in a rat sepsis model
Xiaoli Li et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients
Xiao-bin Lin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients
Osamu Imataki et al.
TRANSPLANT INFECTIOUS DISEASE (2018)
The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo
Miao Yan et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society
Ken Chen et al.
THERAPEUTIC DRUG MONITORING (2018)
Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole
Fang Qi et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review
T. -y. Li et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes
Beibei Shao et al.
XENOBIOTICA (2017)
Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped
E. Gautier-Veyret et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
B. Moriyama et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450 (CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers
Piergiorgio Cojutti et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)
A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?
Elodie Gautier-Veyret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
Haiying Jin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels
Elodie Gautier-Veyret et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients
Takafumi Naito et al.
CLINICA CHIMICA ACTA (2015)
Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital
Evelyn Cabral-Galeano et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2015)
Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians
Prerna K. Chawla et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2015)
Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole
H. -R. He et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction
Petra Matoulkova et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids
Zdenek Dvorak et al.
DRUG METABOLISM REVIEWS (2010)
Pharmacology and clinical use of voriconazole
George R. Thompson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring
Celine Eiden et al.
XENOBIOTICA (2010)
Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
Mats O. Karlsson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development
S. -F. Zhou et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
Marcus J. P. Geist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter
YP Chen et al.
MOLECULAR PHARMACOLOGY (2003)
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
分享论文
